06 agosto 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020, an event that could push the S&P 500 11% higher: "We agree that there is now a good chance that at least one vaccine will be FDA-approved by the end of November and broadly distributed by the middle of 2021," they added.
-
The dangers of Covid-19 far outweigh the risks of a vaccine : So can I tell you that there won't be a long-term unknown side effect to t...
-
The Value of a Cure: An Asset Pricing Perspective : We provide an estimate of the value of a cure using the joint behavior of stock prices ...
-
The Oxford/AstraZeneca Vaccine Efficacy Data : We’re going to have to wait and collect more data to be able to say anything about these, fo...